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ABSTRACT: The histamine H3 receptor (H3R) represents a
highly attractive drug target for the treatment of various central
nervous system disorders, but the discovery of novel H3R targeting
compounds relies on the assessment of highly amplified intra-
cellular signaling events that do not only reflect H3R modulation
and carry the risk of high false-positive and -negative screening
rates. To address these limitations, we designed an intramolecular
H3R biosensor based on the principle of bioluminescence
resonance energy transfer (BRET) that reports the receptor’s
real-time conformational dynamics and provides an advanced tool
to screen for both H3R agonists and inverse agonists in a live cell
screening-compatible assay format. This conformational G-protein-
coupled receptor (GPCR) sensor allowed us to characterize the pharmacological properties of known and new H3 receptor ligands
with unprecedented accuracy. Interestingly, we found that one newly developed H3 receptor ligand possesses even stronger inverse
agonistic activity than reference H3R inverse agonists including the current gold standard pitolisant. Taken together, we describe
here the design and validation of the first screening-compatible H3R conformational biosensor that will aid in the discovery of novel
H3R ligands and can be employed to gain deeper insights into the (in-)activation mechanism of this highly attractive drug target.
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The group of histamine receptors belongs to thesuperfamily of G-protein-coupled receptors (GPCRs)
and comprises four distinct subtypes, named H1, H2, H3, and
H4 receptor (H1−4R), that are of highest interest for modern
drug discovery.1 First, H1R and H2R antagonists have already
been developed in the 1930s and 1970s, respectively, leading
to their extensive medical use in numerous antiallergic and
antiulcer pharmaceutics including loratadine (H1R) and
ranitidine (H2R) that are listed in the WHO register of
essential medicines.2,3
Likewise, the discovery of the subtype H3R has raised
intense hopes for the development of similarly successful
drugs.4 In humans, H3R is almost exclusively expressed in the
central nervous system (CNS) and considered to work both as
an autoreceptor in presynaptic membranes and as a
postsynaptic heteroreceptor controlling the release of other
neurotransmitters including acetylcholine, norepinephrine, and
dopamine.5 Therefore, pharmacological modulation of the
H3R represents an attractive approach to treat various central
nervous system diseases such as Parkinson’s, Huntington’s, and
Alzheimer’s diseases, as well as tic disorders.1,6−9 In addition,
pitolisant, an H3R inverse agonist that reduces the basal
signaling capacity of the receptor (known as receptor
constitutive activity), has entered the market 4 years ago for
the treatment of narcolepsia.10 Despite increasing efforts to
develop novel H3R-modulating compounds,
11−17 thus far,
pitolisant represents the only H3R ligand that is approved by
health authorities. This is partially due to the limited power of
our current screening technologies that are mainly based on
receptor downstream signaling events. For instance, measuring
compound-induced β-arrestin translocation is one of the most
common assays employed in GPCR drug discovery campaigns.
However, this approach not only fails to detect G-protein-
biased H3R agonists but also misses receptor inverse agonists
like pitolisant. Identification of pitolisant with such a setup
would instead require preincubation with selective H3R
agonists but, in turn, hamper the discovery of H3 receptor
agonists.
In contrast to these signaling-dependent assays, down-
stream-independent screening methods that detect ligands
with distinct efficacies (e.g., agonists vs inverse agonists) and
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specific downstream signaling profiles (e.g., G-protein-biased
vs β-arrestin-biased agonists) would allow for the simultaneous
screening of compounds with differing pharmacological
profiles and thus are highly desired to speed up the discovery
of novel GPCR ligands.
Conformational GPCR biosensors based on fluorescence
and bioluminescence resonance energy transfer (FRET and
BRET, respectively) have proven valuable tools to determine
the pharmacological profiles of GPCR ligands in a real-time
and live cell assay system.18 Since the receptor’s conforma-
tional change follows directly upon ligand binding without any
signal amplification, this approach represents the most
undistorted way to assess ligand efficacy and potency; as a
consequence, these conformational readouts reveal differences
among distinct test compounds where downstream-dependent
assays report indiscernible activities.19−21 Furthermore, single-
cell studies employing FRET-based conformational biosensors
of H1R and H3R have recently provided precious insights into
the mechano-sensing mechanism and the activation kinetics of
histamine receptors, respectively.22,23 Recently, the suitability
of such sensors for high-throughput screening has been
demonstrated by employing a novel BRET system composed
of the small engineered luciferase NanoLuciferase (Nluc)24
and a red fluorescent HaloTag dye,25 as demonstrated for two
class A (α2A-adrenergic and β2-adrenergic receptor) and one
class B GPCRs (parathyroid hormone receptor 1).19
In this study, we set out to address the urgent need for a
downstream-independent and very sensitive screening platform
for the highly attractive drug target, the H3R. By fusing the
BRET partners Nluc and HaloTag to this histamine receptor
subtype, we generated a conformational biosensor that enabled
the simultaneous detection of agonists and inverse agonists
with screening-compatible assay sensitivity. Furthermore, using
this biosensor, we characterized pharmacologically, in addition
to several well-known H3R standard ligands, two novel H3R
inverse agonists, which have recently been identified in a
virtual screening campaign.26 We show that one of these
ligands possesses even stronger inverse agonistic activity than
pitolisant and reduces the H3R-mediated Gi-protein activity
with nanomolar potencies.
■ EXPERIMENTAL SECTION
Plasmids. Wild-type human H3R DNA (GeneID 11255) in
pcDNA3.1 vector was purchased from cDNA.org. Nluc was fused at
position K445 to generate C-terminally tagged H3RNluc. Thereafter, a
HaloTag was inserted between S307/G308 (full-length
H3RNluc/Halo(618)) or between T229/F348 (Δicl3-H3RNluc/Halo(618))
within the third intracellular loop of H3RNluc. All cloning steps were
performed using the established polymerase chain reaction (PCR)
strategies, and restriction enzymes and constructs were verified by
sequencing (Eurofins genomics). Plasmids encoding tagged and
native G-protein subunits were kindly provided by A. Inoue (Tohoku
University, Sendai, Japan).
Reagents. Histamine dihydrochloride, imetit dihydrobromide,
clobenpropit dihydrobromide, thioperamide, and pitolisant (BF 2649
hydrochloride) were purchased from Tocris Bioscience (Wiesbaden-
Nordenstadt, Germany). Poly-D-lysine and geneticin were obtained
from Sigma-Aldrich (Taufkirchen, Germany). [3H]NAMH (specific
activity: 79.7 Ci/mmol) was from PerkinElmer (Waltham, MA).
Z27743747 and Z3303614736 were purchased from Enamine Ltd.
(Kyiv, Ukraine). The Nluc substrate furimazine and the HaloTag
fluorescent dye NanoBRET 618 were obtained from Promega
(Madison, WI). UR-PI294, VUF4903, VUF4904, and VUF5207
were synthesized as described previously.27,28 White-wall, white-
bottomed 96-well microtiter plates were from Brand (Wertheim,
Germany) and Gibco (Waltham, MA).
Cell Culture. HEK293T and HEK293A cells were used for the
transient expression of GPCR and G-protein biosensors and grown in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 2
mM glutamine, 10% fetal calf serum, 0.1 mg/mL streptomycin, and
100 units/mL penicillin at 37 °C with 5% CO2. To generate the cell
line stably expressing Δicl3-H3RNluc/Halo(618), HEK293A cells grown in
T75 flasks were transfected at a confluence of 50% with 1 μg of DNA
using Lipofectamine 2000 (ThermoFisher Scientific, Waltham, MA).
Stably transfected cells were selected with 2 mg/mL geneticin and
maintained in supplemented DMEM containing 500 μg/mL
geneticin.
Radioligand Binding. HEK293A cells stably expressing Δicl3-
H3RNluc/Halo(618) or HEK293T cells transiently transfected with 2.5 μg
of the wild-type H3R cDNA grown in 10 cm
2 culture dishes were
collected (48 h after transfection for the wild-type H3R) in cold
phosphate-buffered saline (PBS) and centrifuged at 3000g for 15 min
at 4 °C. The supernatant was discarded, and the cell pellet was stored
at −20 °C until the day of the experiment. Prior to the experiment,
cell pellets (200 μg/mL) were resuspended in binding buffer (50 mM
Tris−HCl, pH 7.4) and disrupted using a Branson 250 sonifier
(Boom B.V., Meppel, The Netherlands).
For saturation binding, 50 μL of cell pellets were incubated with
increasing concentrations of [3H]NAMH for 2 h at 25 °C.
Nonspecific binding was measured in the presence of 100 μM
histamine. Equilibrium competition binding was assayed on 50 μL of
cell homogenates with 2 nM [3H]NAMH in the absence and presence
of increasing concentrations of unlabelled ligands for 2 h at 25 °C. To
terminate incubation, homogenates were filtered over a 0.5%
polyethyleneimine (PEI)-coated 96-well GF/C filter plate using a
PerkinElmer 96-well Filtermate-harvester. After three rapid wash steps
with ice-cold binding buffer, the GF/C filter plates were dried at 55
°C. Subsequently, 25 μL of Microscint-O scintillation liquid
(PerkinElmer, Groningen, The Netherlands) was added per well
and incubated for 2 h to quantify filter-bound radioactivity using a
Microbeta Wallac Trilux scintillation counter (PerkinElmer).
Transient Transfection and Plating. The day before transient
transfection, 1.5 × 106 HEK293T (for G-protein experiments) or
HEK293A cells (for H3R conformational sensors) were seeded in T25
flasks. The next day, 1 μg of pcDNA3.1 plasmid encoding either of the
two H3R biosensors was transfected using Lipofectamine 2000. For
G-protein experiments, the cells were transfected with 200 ng of
LargeBit-Gαi1, 1 μg of Gβ5-smallBit, 1 μg of Gγ2, and 400 ng of wild-
type H3R plasmids. Twenty-four hours after transfection, the cells
were resuspended in supplemented DMEM, mixed with 50 nM
HaloTag NanoBret 618 if H3R conformational biosensors were
transfected, and transferred to poly-D-lysine-precoated white 96-well
plates at a density of 50 000 cells/well.
Recording of BRET Emission Spectra. HEK293T cells were
transfected and labeled as described above. Luminescence emission
spectra of H3R sensors were recorded in HBSS with 4 nm resolution
upon addition of 1:1000 furimazine dilution using a CLARIOstar
plate reader (BMG, Ortenberg, Germany). Spectra were normalized
to the donor emission peak.
BRET and Luminescence Measurements. Cells transiently or
stably expressing the H3R biosensors or H3R wild-type along with
native and tagged G-protein subunits were washed with HBSS and
incubated with 1/1000 dilution of furimazine stock solution. After
incubation for 3 min at 37 °C, the basal BRET ratio (H3R biosensor)
or absolute Nluc luminescence (G-protein) was measured. Sub-
sequently, 10 μL of 10-fold ligand solution or vehicle control was
applied per well and the stimulated BRET ratio or luminescence was
recorded. All experiments were conducted at 37 °C with a Synergy
Neo2 (Biotek, Winooski, VT) or a CLARIOstar plate reader. Nluc
emission intensity was selected using a 460/40 nm filter (Neo2) or a
450/50 nm monochromator (CLARIOstar). For HaloTag Nano-
BRET 618, a 620/20 nm filter or a 620/30 nm monochromator was
used. All experiments were conducted with an integration time of 0.3
s.
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Data Analysis and Statistics. BRET ratios were defined as
acceptor emission/donor emission. Three individual luminescence or
BRET values were averaged before and after ligand addition (lumbasal
and lumstim; ratiobasal and ratiostim, respectively). To quantify ligand-
induced changes, Δluminescence (Δlum) and ΔBRET were
calculated for each well as a percent over basal ([(lumstim −
lumbasal)/lumbasal] × 100; [(ratiostim − ratiobasal)/ratiobasal] × 100).
Subsequently, the average Δlum/ΔBRET of vehicle control was
subtracted. The Z-factors were calculated based on the following
equation
Z factor 1
(3 compound 3 vehicle )
( compound vehicle )
σ σ
μ μ
− = − × [ ] + × [ ]
[ ] − [ ]
where σ and μ are the standard deviations (SDs) and average ΔBRET
values of 10 μM histamine and vehicle control, respectively. For the
Z-factor experiments using pitolisant as a positive control, the
denominator in the equation was replaced by “(μ[vehicle] −
μ[compound])”.
Signal-to-noise (S/N) ratios in the Δicl3-H3RNluc/Halo(618) assay were
calculated according to the following equation
S/N
average BRET vehicle average BRET compound
standard deviation vehicle
= Δ [ ] − Δ [ ]
[ ]
S/N ratios in the split Nluc-based Gi1 assay were calculated according
to the following equation
S/N
average lum compound average lum vehicle
standard deviation vehicle
= Δ [ ] − Δ [ ]
[ ]
Data were analyzed using Prism 5.0 software (GraphPad, San
Diego, CA). The data from BRET and luminescence concentration−
response experiments were fitted using a four-parameter fit. Data from
radioligand saturation binding experiments were fitted using a one-site
fitting model. Competition-binding curves were fitted to a one-site
binding model to obtain the IC50 value. Equilibrium dissociation
constants (Ki) of unlabeled ligands were subsequently calculated using
the Cheng−Prusoff equation
K
K
IC
1 L /i
50
D
=
+ [ ]
where [L] is the concentration of the labeled ligand and KD is the
equilibrium dissociation constant of the labeled ligand. Statistical
differences were assessed by one-way ANOVA followed by Bonferroni
multiple comparison or extra-sum-of-squares F-test. Differences were
considered significant for values of p < 0.05.
■ RESULTS AND DISCUSSION
Design and Comparison of Two H3R Conformational
Biosensor Versions. The development of ligand-sensitive
conformational GPCR biosensors often requires the testing of
different (i) resonance energy partner combinations, (ii)
Scheme 1. Principle of the Sensor and Assay Designa
a(a) BRET partners HaloTag and Nluc are fused to the third intracellular loop and C-terminus of the histamine H3 receptor, respectively. The
proximity of the BRET patners allows for energy transfer from the donor Nluc to HaloTag. Upon binding of full agonists or full inverse agonists,
the receptor undergoes conformational changes to the fully active (top right) or inactive (bottom right) state, affecting the efficiency of energy
transfer. (b) Assay protocol. (c) Insertion sites of Nluc and HaloTag in two H3R biosensor versions.
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insertion sites for the FRET and BRET tags, or (iii) major
modifications of the original receptor sequence.
We have previously shown that the combination of Nluc and
HaloTag(618) yields the most sensitive conformational
sensors for three model GPCRs19 and therefore employed
this BRET pair to create two distinct variants of conforma-
tional H3RNluc/Halo biosensors and monitor their conforma-
tional dynamics in a 96-well microtiter format (Scheme 1a,b).
To minimize the manipulation of the natural H3 receptor, we
first generated a full-length H3R sensor version by placing
HaloTag between S307 and G308 in the third intracellular
loop (icl3) and fusing NanoLuc to the C-terminal amino acid
K445 (full-length H3RNluc/Halo(618)). In some previously
published conformational GPCR sensors, a long icl3, as it is
also present in H3R (142 amino acids), has been associated
with issues for sensor engineering and was truncated to yield a
ligand-sensitive biosensor.29−31 Thus, in a second approach, we
took advantage of a previously validated FRET-based H3R
conformational sensor design that enabled the assessment of
H3R activation kinetics in a single-cell assay format.
23 In
compliance with this sensor design, we fused Nluc to K445 and
placed HaloTag between amino acids T229 and F348 to
generate an analogous BRET H3R conformational sensor
(Δicl3-H3RNluc/Halo(618)) and monitor ligand−H3R interaction
in a 96-well microtiter format (Scheme 1c).23
These two sensor constructs were transiently expressed in
HEK293 cells to record the luminescence emission spectra
upon addition of the Nluc substrate furimazine (Figure 1a,b).
Both variants displayed the typical Nluc emission maximum
around 450 nm and an additional peak at 620 nm. The latter is
specific for the BRET acceptor fluorophore HaloTag(618) and
indicates resonance energy transfer in the basal ligand-free
states of both biosensors. Subsequently, we assessed the ability
of these sensor variants to detect the GPCR conformational
dynamics upon the addition of the well-characterized H3R
ligands histamine (endogenous full agonist), imetit (synthetic
full agonist), clobenpropit (inverse agonist), and pitolisant
(inverse agonist) (Chart 1).
We incubated HEK293 cells transiently expressing either of
the two sensor versions with these reference ligands or vehicle
control and recorded the resulting change in BRET over
baseline in 96-well microtiter plates. These experiments
revealed that the full-length H3RNluc/Halo(618) does not detect
the conformational dynamics of the H3R since no significant
BRET change was observed (Figure 1c). In contrast, the BRET
ratio of Δicl3-H3RNluc/Halo(618) expressing cells increased upon
stimulation with the two full agonists histamine and imetit and
decreased slightly after the addition of the inverse agonist
pitolisant (Figure 1d).
Validation of Δ icl3-H3RNluc /Ha lo . The Δ ic l3-
H3RNluc/Halo(618) biosensor proved capable of detecting the
ligand-induced receptor conformational changes in transiently
transfected HEK293 cells (Figure 1d). To evaluate the ligand-
binding properties of Δicl3-H3RNluc/Halo(618), we next con-
ducted classical radioligand saturation binding experiments.
Here, binding of the radiolabeled H3R agonist N-α-methylhist-
amine ([3H]NAMH) saturated with a pKD of 8.7 ± 0.2 (mean
± SD), similar to what we observed with cells expressing wild-
type H3R (pKD = 8.9 ± 0.1) (Figure 2a and Supporting Table
1). In addition, radioligand displacement experiments at Δicl3-
H3RNluc/Halo(618) with a panel of H3R reference ligands yielded
pKi values that were in general accordance with the previously
published data (Figure 2b, Supporting Table 1 and Figure 1).
Importantly, Δicl3-H3RNluc/Halo(618) maintains the distinct
binding affinities for the enantiomers (R)-α-methylhistamine
(RAMH) and (S)-α-methylhistamine (SAMH) known from
wild-type H3R. Taken together, these binding experiments
reveal that Δicl3-H3RNluc/Halo(618), similar to its original FRET
analogue,23 possesses wild-type binding properties, which
represents a key requirement for its utility in ligand screening
experiments.
To improve the assay’s dynamic range, we next generated a
HEK293 cell line stably expressing Δicl3-H3RNluc/Halo(618) and
conducted live cell BRET experiments to demonstrate its
suitability to study the pharmacology of H3R ligands.
Therefore, we first stimulated these sensor cells with 10 μM
of six reference H3R ligands (histamine, imetit, UR-PI294,
thioperamide, clobenpropit, and pitolisant) that possess
distinct intrinsic efficacies ranging from full agonism to inverse
agonism (Chart 1 and Supporting Table 1). The BRET time-
courses plateaued within several minutes after ligand addition
and remained stable for at least 40 min (Figure 3a). The
stability of the BRET response illustrates the broad time
window for signal detection and underlines the applicability of
this assay for automated screening conditions where stacked
ligand-treated microtiter plates are read consecutively.
Furthermore, all reference ligands yielded saturating BRET
concentration−response curves and the EC50-based order of
potency resembled the pKi-based order of affinity from our
previous binding experiments (Figure 3b and Supporting Table
1). For few ligands, however, we obtained distinct affinities/
potencies using the radioligand displacement assay in cell
lysates or the BRET-based conformational readout in intact
cells (e.g., for clobenpropit). Similar deviations have been
reported recently for H3R ligand affinities assessed in either
radioligand displacement or NanoBRET binding experiments
on the very same Nluc-tagged H3R construct.
32 Therefore, we
Figure 1. Comparison of two H3RNluc/Halo(618) biosensor versions. (a,
b) Representative luminescence emission spectra of full-length
H3RNluc/Halo(618) (a) and Δicl3-H3RNluc/Halo(618) (b). (c, d) BRET
changes reported by full-length H3RNluc/Halo(618) (c) and Δicl3-
H3RNluc/Halo(618) (d) upon addition of H3R reference ligands. All
experiments were conducted in HEK293 cells transiently transfected
with the indicated biosensor. Data in (c) and (d) show pooled data
from three independent experiments. *p < 0.05 vs vehicle control.
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suppose that differences in assay conditions (e.g., buffer
composition or receptor environment in intact cells vs cell
lysates) account for the few deviations observed in our
experiments.
Of note, the three agonists histamine, imetit, and UR-PI294
elevated the BRET ratio with distinct maximal effects (Emax).
To the best of our knowledge, this is the first data indicating
that imetit behaves as a strong partial rather than a full agonist
at the receptor level. In contrast to the increase in BRET
evoked by agonists, the H3R inverse agonists thioperamide,
clobenpropit, and pitolisant induced a reduction in BRET, in
line with their distinct downstream effects. However,
surprisingly, thioperamide, clobenpropit, and pitolisant pla-
teaued at different BRET signals (Emax of pitolisant >
clobenpropit > thioperamide), similar to the differences we
observed for agonists, i.e., imetit and histamine. This suggests
that also these ligands possess distinct inverse efficacies, with
pitolisant being the strongest inverse agonist.
Next, we aimed to explore whether Δicl3-H3RNluc/Halo(618)
can be utilized to conduct structure-activity-relationship (SAR)
studies with H3R ligands. We selected a panel of three
chemical analogues of the H3R agonist impentamine that
present distinct chemical substitutions at the amine group
(Chart 1). When characterized at the second messenger cyclic
adenosine monophosphate (cAMP) level, these ligands
displayed varying efficacies ranging from strong partial agonism
for impentamine to inverse agonism for VUF4903 (Supporting
Table 1).28 The conformational H3R sensor Δicl3-
H3RNluc/Halo(618) detected these differential ligand activities
and reported partial agonistic responses for the parent
compound impentamine and its analogue VUF5207, as well
as inverse agonistic responses with distinct Emax values for
VUF4904 and VUF4903 (Figure 3c and Supporting Table 1).
Overall, these results demonstrate that Δicl3-H3RNluc/Halo(618)
provides a valuable tool to conduct SAR studies of H3R ligands
at the level of receptor conformation.
Last, we aimed to evaluate the sensitivity and reproducibility
of this sensor cell line to screen simultaneously H3R agonists
and inverse agonists in a single high-throughput campaign (i.e.,
without the requirement to preincubate the cells with
competing H3R ligands). Therefore, we measured the Z-
factors for agonists and inverse agonists by applying either
histamine or pitolisant as a positive control, respectively.33 The
Chart 1. Chemical Structures of Histamine H3 Receptor Agonists and Inverse Agonists Applied in This Study
Figure 2. Ligand-binding properties of Δicl3-H3RNluc/Halo(618). (a)
Saturation binding of the radiolabeled H3R agonist [
3H]NAMH to
the wild-type H3R and Δicl3-H3RNlucHalo(618). (b) Correlation of
ligand-binding affinities to the wild-type H3R (values extracted from
literature except for [3H]NAMH; see also Supporting Table 1) and
Δicl3-H3RNlucHalo(618) (red: agonists; blue: inverse agonists). Dotted
line indicates line of unity. Experiments were conducted using
membranes from transiently (a) or stably expressing (b) HEK293
cells. Data show the mean ± standard error of mean (SEM) of one
representative (a) or at least three independent experiments (b).
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resulting average Z-factors were well above 0.5 (histamine:
0.58 ± 0.02; pitolisant: 0.72 ± 0.02; mean ± SEM) and
showed low interday variability (histamine: 4.6%; pitolisant:
5.6%; coefficient of variation), highlighting the substantial
agonist and inverse agonist screening windows and the
robustness of this conformational readout (Figure 3d−f and
Supporting Figure 2). These results underline the applicability
of this conformational biosensor to screen for and characterize
novel H3R ligands with varying intrinsic activities using the
same experimental setup.
Pharmacological Characterization of Two Novel H3R
Inverse Agonists. To further demonstrate the ability of the
conformational biosensor to characterize new H3R targeting
compounds, we used it to assess the pharmacological
properties of two new H3R ligands, Z27743747 and
Z3303614736 (Chart 1). These compounds were discovered
in a recent in-silico docking screen and validated for binding
H3R with nanomolar affinities.
26 However, further information
on the pharmacological properties of Z27743747 and
Z3303614736 is lacking, and this is hampering a reliable
evaluation of their potential as novel H3R modulating lead
structures. We first incubated the stable H3R biosensor cell line
with 10 μM of either compound and in parallel conducted the
same experiments using our previously described conforma-
t iona l b iosensor of the β 2 -adrenerg ic receptor
(β2ARNluc/Halo).
19 Both ligands evoked fast and stable negative
BRET changes in H3RNluc/Halo expressing cells but, as control,
no BRET signals were observed in β2ARNluc/Halo (Figure 4a,b).
Furthermore, application of increasing compound concen-
trations yielded sigmoidal concentration−response curves with
nanomolar EC50-values for H3RNluc/Halo but not β2ARNluc/Halo
(Figure 4c,d and Supporting Table 1). Of note, Z27743747
evoked an even stronger BRET response than the reference
inverse agonist pitolisant (Supporting Table 1 and Figure 3),
indicating that this ligand presents a promising chemical
scaffold for the development of novel H3R ligands with even
greater intrinsic inverse agonistic activity.
To verify these data on a receptor downstream level, we
employed a split luciferase complementation-based readout
reflecting the G-protein activity.34 We co-expressed Gαi1 and
Gβ5 subunits tagged with complementary Nluc fragments along
with native Gγ2 and wild-type H3R in HEK293 cells and pre-
stimulated with 300 nM histamine to induce the dissociation of
the heterotrimeric G-protein complex.
Upon the addition of 10 μM Z27743747 or Z3303614736,
the luminescence intensity increased and peaked within several
minutes, corresponding to a reassembly of the heterotrimeric
G-protein complex (Figure 4e). Moreover, these signals were
Figure 3. Validation of the Δicl3-H3RNluc/Halo(618) biosensor. (a)
ΔBRET time-course of six reference ligands (legend in b). (b) BRET
concentration−response curves of six reference ligands. (c)
Concentration−response curves of impentamine and three structural
analogues. (d) Z-factors of Δicl3-H3RNluc/Halo(618) to assess the
screening windows for H3R agonists and inverse agonists. (e)
BRET signals of one representative 96-well plate treated with 10
μM histamine or vehicle. (f) BRET signals of one representative 96-
well plate treated with 10 μM pitolisant or vehicle. All experiments
were conducted in HEK293 cells stably expressing the Δicl3-
H3RNluc/Halo(618) biosensor. Data in (a)−(d) show the mean ± SEM
of at least three independent experiments.
Figure 4. Characterization of new H3R inverse agonists. (a, b)
ΔBRET time-course of Δicl3-H3RNluc/Halo(618) and β2ARNluc/Halo(618)
upon addition of Z27743747 (a) and Z3303614736 (b). (c, d)
Concentration−response curves of Z27743747 (c) and Z3303614736
(d) applied to cells expressing Δicl3-H3RNluc/Halo(618) or
β2ARNluc/Halo(618). (e, f) ΔLuminescence time-course (e) and
concentration−response (f) of the split Nluc-based G-protein sensor
upon treatment with Z27743747 or Z3303614736. Experiments in
(a)−(d) were conducted in HEK293 cells stably expressing either of
the two conformational GPCR biosensors. Experiments in (e) and (f)
were conducted in HEK293 cells transiently transfected with H3R
wild-type and the split Nluc-based Gi1 sensor and pre-stimulated with
300 nM histamine (for 5 min before time point 0). Data show the
mean ± SEM of at least three independent experiments.
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concentration-dependent and resulted in very similar IC50
values as measured with the H3R conformational biosensor
(Z27743747: 6.90 ± 0.11; Z3303614736: 7.03 ± 0.07; pIC50
± SD) (Figure 4f and Supporting Table 1). Of note, only
Z27743747, but not Z3303614736, was also able to induce an
increase in G-protein luminescence when applied to basal H3R
(i.e., without 300 nM histamine preincubation) demonstrating
its stronger inverse activity compared to that of Z3303614736
(Supporting Figure 4a). However, the signal-to-noise ratio (S/
N) of this luminescence increase was substantially lower as
compared to (i) that of histamine pre-stimulated H3R-Gi
condition and (ii) the S/N ratio assessed with Δicl3-
H3RNluc/Halo(618) (also without agonist pre-stimulation) (Sup-
porting Figure 4b).
Taken together, these results demonstrate that Z27743747
and Z3303614736 are new strong inverse agonists of H3R that
inactivate the receptor with nanomolar potencies. Additionally,
comparison of the different assay systems (Δicl3-
H3RNluc/Halo(618) vs H3R wild-type plus Gi1 sensor) underlines
the accuracy and outstanding sensitivity of the new conforma-
tional H3R biosensor to identify and characterize novel H3R
inverse agonist.
■ CONCLUSIONS
The histamine H3 receptor is involved in multiple CNS
disorders and rated among the most attractive and most
targeted GPCRs by compounds in clinical trials.35 Despite the
extensive interest in regulating this receptor with new
pharmaceutics, pitolisant represents so far the only approved
H3R-targeting drug partially due to the limitations of current
H3R-suited screening assays. In this work, we describe a new
screening-compatible biosensor to aid in the future identi-
fication and pharmacological assessment of H3R-modulating
compounds.
Novel H3R Conformational Biosensor Allows for the
Synchronous Screening of Agonists and Inverse
Agonists. This new biosensor is composed of the BRET
partners Nluc and a red fluorescent HaloTag dye fused to H3R
to translate the ligand-induced conformational dynamics of this
receptor into optical signals.
We show that this sensor maintains wild-type-like ligand-
binding properties and facilitates the assessment of ligand
potency and efficacy at the most proximal level, i.e., directly
after ligand binding. Consequently, we were able to detect
differences in ligand efficacies between the two H3R agonists
histamine and imetit as well as between the inverse agonists
thioperamide, clobenpropit, and pitolisant (Supporting Table
1). These distinct intrinsic activities could not be observed in
previous studies using the FRET-based conformational H3R
sensor23 or downstream-dependent H3R assays,
36 which might
be a consequence of differential sensitivities of FRET- vs
BRET-based sensors37 or, with respect to histamine and imetit,
be due to the impact of signal amplification in downstream-
dependent assays. Supporting this hypothesis, similar discrep-
ancies between ligand efficacies assessed with FRET vs BRET
conformational sensors (UK 14 304 response at α2AARCFP/Flash
vs α2AARNluc/Halo(618))
19,38 and downstream vs receptor
conformation assays have been reported for the α2A-adrenergic
(norepinephrine vs UK 14 304) and β2-adrenergic receptor
(epinephrine vs norepinephrine).19−21 Our findings with the
H3R conformational biosensor underline the superior reso-
lution provided by conformational GPCR sensors for the
determination of ligand efficacies.
Furthermore, we demonstrate that the H3R biosensor can be
employed to explore structure−activity relationships and
provides excellent sensitivity and robustness for the simulta-
neous screening of H3R agonists and inverse agonists. This
feature is of great value in GPCR-targeted ligand screening
campaigns since, in contrast to downstream-dependent assays,
no preincubation with (or subsequent addition of) an H3R
agonists is required to identify inverse agonists or vice versa.
To the best of our knowledge, such a screening-compatible
and uniform assay format is not provided by any other GPCR
screening technology available today.
Characterization of Novel H3R Ligands with Marked
Inverse Agonistic Efficacy. In the last part of this study, we
employed the novel H3R conformational sensor to assess the
pharmacological properties of two new H3R ligands that were
recently discovered through virtual screening.26 Both com-
pounds bind H3R with nanomolar affinity, but their intrinsic
efficacies have not been determined so far. Interestingly, our
results with the H3R conformational biosensor revealed
pronounced inverse agonistic responses of the ligands
Z27743747 and Z3303614736. In particular, Z27743747
induced even higher BRET amplitudes than the validated
inverse agonists thioperamide, clobenpropit, and pitolisant.
This suggests that Z27743747 presents a stronger inverse
agonistic activity than the current gold standard pitolisant
(Supporting Table 1 and Figure 3) by stabilizing a distinct
conformation of H3R that is characterized by no or very little
residual receptor signaling capacity.
Therefore, Z27743747 and Z3303614736 represent two
promising H3R lead structures with novel chemical scaffolds
that can help in designing superior H3R ligands with
advantageous pharmacodynamic properties.
Taken together, this work describes the successful
generation of the first screening applicable H3R conformational
sensor. This optical tool will aid in the development of novel
receptor ligands and may be employed to gain new insights
into the molecular mechanisms underlying H3R conforma-
tional dynamics. The successful implementation of this sensor
design for the H3R opens up the possibility to expand this
technique to other class A GPCRs, e.g., other members of the
histamine receptor family, to assess the pharmacological
properties of GPCR ligands directly at the level of receptor
conformation.
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(17) Łazėwska, D.; Kiec-́Kononowicz, K. Progress in the develop-
ment of histamine H3 receptor antagonists/inverse agonists: a patent
review (2013-2017). Expert Opin. Ther. Pat. 2018, 28, 175−196.
(18) Lohse, M. J.; Nuber, S.; Hoffmann, C. Fluorescence/
bioluminescence resonance energy transfer techniques to study G-
protein-coupled receptor activation and signaling. Pharmacol. Rev.
2012, 64, 299−336.
(19) Schihada, H.; Vandenabeele, S.; Zabel, U.; Frank, M.; Lohse,
M. J.; Maiellaro, I. A universal bioluminescence resonance energy
transfer sensor design enables high-sensitivity screening of GPCR
activation dynamics. Commun. Biol. 2018, 1, No. 105.
(20) Reiner, S.; Ambrosio, M.; Hoffmann, C.; Lohse, M. J.
Differential signaling of the endogenous agonists at the beta2-
adrenergic receptor. J. Biol. Chem. 2010, 285, 36188−36198.
(21) Liu, J. J.; Horst, R.; Katritch, V.; Stevens, R. C.; Wuthrich, K.
Biased signaling pathways in beta2-adrenergic receptor characterized
by 19F-NMR. Science 2012, 335, 1106−1110.
(22) Erdogmus, S.; Storch, U.; Danner, L.; Becker, J.; Winter, M.;
Ziegler, N.; Wirth, A.; Offermanns, S.; Hoffmann, C.; Gudermann, T.;
y Mederos, M. M. Helix 8 is the essential structural motif of
mechanosensitive GPCRs. Nat. Commun. 2019, 10, No. 5784.
(23) Liu, Y.; Zeng, H.; Pediani, J. D.; Ward, R. J.; Chen, L.-Y.; Wu,
N.; Ma, L.; Tang, M.; Yang, Y.; An, S.; Guo, X. -X.; Hao, Q.; Xu, T. R.
Visualization of the activation of the histamine H3 receptor (H3R)
using novel fluorescence resonance energy transfer biosensors and
their potential application to the study of H3R pharmacology. FEBS J.
2018, 285, 2319−2336.
(24) Hall, M. P.; Unch, J.; Binkowski, B. F.; Valley, M. P.; Butler, B.
L.; Wood, M. G.; Otto, P.; Zimmerman, K.; Vidugiris, G.; Machleidt,
T.; Robers, M. B.; Benink, H. A.; Eggers, C. T.; Slater, M. R.;
Meisenheimer, P. L.; Klaubert, D. H.; Fan, F.; Encell, L. P.; Wood, K.
V. Engineered luciferase reporter from a deep sea shrimp utilizing a
novel imidazopyrazinone substrate. ACS Chem Biol 2012, 7, 1848−
1857.
(25) Los, G. V.; Encell, L. P.; McDougall, M. G.; Hartzell, D. D.;
Karassina, N.; Zimprich, C.; Wood, M. G.; Learish, R.; Ohana, R. F.;
Urh, M.; Simpson, D.; Mendez, J.; Zimmerman, K.; Otto, P.;
Vidugiris, G.; Zhu, J.; Darzins, A.; Klaubert, D. H.; Bulleit, R. F.;
Wood, K. V. HaloTag: a novel protein labeling technology for cell
imaging and protein analysis. ACS Chem Biol 2008, 3, 373−382.
(26) Schaller, D.; Hagenow, S.; Stark, H.; Wolber, G. Ligand-guided
homology modeling drives identification of novel histamine H3
receptor ligands. PLoS One 2019, 14, No. e0218820.
(27) Igel, P.; Schnell, D.; Bernhardt, G.; Seifert, R.; Buschauer, A.
Tritium-labeled N(1)-[3-(1H-imidazol-4-yl)propyl]-N(2)-propionyl-
guanidine ([(3)H]UR-PI294), a high-affinity histamine H(3) and
H(4) receptor radioligand. ChemMedChem 2009, 4, 225−231.
(28) Wieland, K.; Bongers, G.; Yamamoto, Y.; Hashimoto, T.;
Yamatodani, A.; Menge, W. M. B. P.; Timmerman, H.; Lovenberg, T.
W.; Leurs, R. Constitutive activity of histamine h(3) receptors stably
expressed in SK-N-MC cells: display of agonism and inverse agonism
by H(3) antagonists. J. Pharmacol. Exp. Ther. 2001, 299, 908−914.
(29) Vilardaga, J.-P.; Bünemann, M.; Krasel, C.; Castro, M.; Lohse,
M. J. Measurement of the millisecond activation switch of G protein-
coupled receptors in living cells. Nat. Biotechnol. 2003, 21, 807−812.
(30) Hoffmann, C.; Gaietta, G.; Bünemann, M.; Adams, S. R.;
Oberdorff-Maass, S.; Behr, B.; Vilardaga, J.-P.; Tsien, R. Y.; Ellisman,
M. H.; Lohse, M. J. A FlAsH-based FRET approach to determine G
protein-coupled receptor activation in living cells. Nat. Methods 2005,
2, 171−176.
(31) Kauk, M.; Hoffmann, C. Intramolecular and Intermolecular
FRET Sensors for GPCRs - Monitoring Conformational Changes and
Beyond. Trends Pharmacol. Sci. 2018, 39, 123−135.
(32) Mocking, T. A. M.; Verweij, E. W. E.; Vischer, H. F.; Leurs, R.
Homogeneous, Real-Time NanoBRET Binding Assays for the
Histamine H3 and H4 Receptors on Living Cells. Mol. Pharmacol.
2018, 94, 1371−1381.
(33) Zhang, J.-H.; Chung, T. D. Y.; Oldenburg, K. R. A Simple
Statistical Parameter for Use in Evaluation and Validation of High
Throughput Screening Assays. J. Biomol. Screening 1999, 4, 67−73.
(34) Inoue, A.; Raimondi, F.; Kadji, F. M. N.; Singh, G.; Kishi, T.;
Uwamizu, A.; Ono, Y.; Shinjo, Y.; Ishida, S.; Arang, N.; Kawakami, K.;
Gutkind, J. S.; Aoki, J.; Russell, R. B. Illuminating G-Protein-Coupling
Selectivity of GPCRs. Cell 2019, 177, 1933−1947.
(35) Hauser, A. S.; Attwood, M. M.; Rask-Andersen, M.; Schioth, H.
B.; Gloriam, D. E. Trends in GPCR drug discovery: new agents,
targets and indications. Nat. Rev. Drug Discovery 2017, 16, 829−842.
(36) Lim, H. D.; van Rijn, R. M.; Ling, P.; Bakker, R. A.; Thurmond,
R. L.; Leurs, R. Evaluation of histamine H1-, H2-, and H3-receptor
ligands at the human histamine H4 receptor: identification of 4-
methylhistamine as the first potent and selective H4 receptor agonist.
J. Pharmacol. Exp. Ther. 2005, 314, 1310−1321.
(37) Boute, N.; Jockers, R.; Issad, T. The use of resonance energy
transfer in high-throughput screening: BRET versus FRET. Trends
Pharmacol. Sci. 2002, 23, 351−354.
(38) Nikolaev, V. O.; Hoffmann, C.; Bünemann, M.; Lohse, M. J.;
Vilardaga, J.-P. Molecular basis of partial agonism at the neuro-
transmitter alpha2A-adrenergic receptor and Gi-protein heterotrimer.
J. Biol. Chem. 2006, 281, 24506−24511.
ACS Sensors pubs.acs.org/acssensors Article
https://dx.doi.org/10.1021/acssensors.0c00397
ACS Sens. 2020, 5, 1734−1742
1742
